Italia markets closed

NuCana plc (N04A.F)

Frankfurt - Frankfurt Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
1,6300+0,1800 (+12,41%)
Al 04:14PM CEST. Mercato aperto.
Schermo intero
Chiusura precedente1,4500
Aperto1,6100
Denaro1,6000 x 0
Lettera1,6300 x 0
Min-Max giorno1,6100 - 1,6300
Intervallo di 52 settimane0,5450 - 2,9000
Volume3.100
Media Volume626
Capitalizzazione93,806M
Beta (5 anni mensile)1,22
Rapporto PE (ttm)N/D
EPS (ttm)-0,8740
Prossima data utili17 ago 2022 - 22 ago 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A9,30
  • GlobeNewswire

    NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

    EDINBURGH, United Kingdom, July 27, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”), announced that it has received a written notification (the “Notification Letter”) from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) and the matter is

  • GlobeNewswire

    German Court Rules that Gilead’s Sofosbuvir Infringes NuCana’s ‘190 Patent

    EDINBURGH, United Kingdom, July 11, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that, following a comprehensive hearing on May 17, 2022, the Regional Court of Dusseldorf (the “Court”) issued a judgement on July 7, 2022 that Gilead Sciences Ireland UC and Gilead Sciences GmbH (together, “Gilead”) infringe NuCana’s composition of matter claims in European Patent 2955190 (the “’190 patent”) through their sales of Sovaldi®, Harvoni®, Vosevi® and Epclusa® in Germany. This judgement f

  • GlobeNewswire

    NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

    NUC-7738 Shows Promising Non-Clinical Activity in Acute Myeloid Leukemia NUC-7738 Kills AML Cells Resistant to Standard Chemotherapy Data Indicates Potential Clinical Utility Beyond Solid Tumors EDINBURGH, United Kingdom, June 10, 2022 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced data to be presented at the European Hematology Association (EHA) 2022 Hybrid Congress highlighting the activity of NUC-7738, a phosphoramidate transformation of 3’-deoxyadenosine (3’-dA), in a broad range of